^
    Back
    Association details:
    Biomarker:FLT3 mutation
    Cancer:Acute Myelogenous Leukemia
    Drug Class:FLT3 inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    BSH-I 2020
    Title:

    Efficacy of FMS-like Tyrosine Kinase 3 (FLT3) inhibitors in patients with acute myeloid leukemia

    Published date:
    01/05/2021
    Excerpt:
    FLT3Is demonstrated a significant improvement in OS in patients with relapsed/ refractory AML and a trend towards improvement in OS in newly diagnosed AML patients…All participants were FLT3 mutated in RATIFY, QuANTUM‐R, and ADMIRAL trials...In patients with newly diagnosed AML (n = 1181), pooled HR for OS showed trend towards statistical significance [0·85, 95% CI: 0·72–1·00, P = 0·05] on analysis of three studies.
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    ASH 2021
    Title:

    1225 Efficacy Analysis of Different FLT3 Inhibitors in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome Patients – a Systematic Review and Meta-Analysis

    Published date:
    11/04/2021
    Excerpt:
    Most FLT3 inhibitors are effective as monotherapy for the treatment of pts with FLT3-mutated-R/R AML.